Vrignaud P - Search Results

1

Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Bissery MC, et al. Among authors: vrignaud p. Anticancer Drugs. 1996 Jun;7(4):437-60. doi: 10.1097/00001813-199606000-00010. Anticancer Drugs. 1996. PMID: 8826613

2

Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.

Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, Riou JF, Commerçon A, Lavelle F, Bissery MC. Vrignaud P, et al. Clin Cancer Res. 2013 Jun 1;19(11):2973-83. doi: 10.1158/1078-0432.CCR-12-3146. Epub 2013 Apr 15. Clin Cancer Res. 2013. PMID: 23589177

3

Preclinical evaluation of docetaxel (Taxotere).

Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Lavelle F, et al. Among authors: vrignaud p. Semin Oncol. 1995 Apr;22(2 Suppl 4):3-16. Semin Oncol. 1995. PMID: 7740328 Review.

4

Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.

Bissery MC, Nguyen CH, Bisagni E, Vrignaud P, Lavelle F. Bissery MC, et al. Among authors: vrignaud p. Invest New Drugs. 1993 Nov;11(4):263-77. doi: 10.1007/BF00874425. Invest New Drugs. 1993. PMID: 8157469

5

Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.

Bissery MC, Vrignaud P, Lavelle F. Bissery MC, et al. Among authors: vrignaud p. Semin Oncol. 1995 Dec;22(6 Suppl 13):3-16. Semin Oncol. 1995. PMID: 8604451

6

Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Bissery MC, et al. Among authors: vrignaud p. Ann N Y Acad Sci. 1996 Dec 13;803:173-80. doi: 10.1111/j.1749-6632.1996.tb26386.x. Ann N Y Acad Sci. 1996. PMID: 8993510 Review. No abstract available.

7

Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.

Nguyen CH, Fan E, Riou JF, Bissery MC, Vrignaud P, Lavelle F, Bisagni E. Nguyen CH, et al. Among authors: vrignaud p. Anticancer Drug Des. 1995 Jun;10(4):277-97. Anticancer Drug Des. 1995. PMID: 7786395

8

Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of taxotere (docetaxel).

Ojima I, Duclos O, Zucco M, Bissery MC, Combeau C, Vrignaud P, Riou JF, Lavelle F. Ojima I, et al. Among authors: vrignaud p. J Med Chem. 1994 Aug 5;37(16):2602-8. doi: 10.1021/jm00042a013. J Med Chem. 1994. PMID: 7914541

9

Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.

Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ. Ojima I, et al. Among authors: vrignaud p. J Med Chem. 1996 Sep 27;39(20):3889-96. doi: 10.1021/jm9604080. J Med Chem. 1996. PMID: 8831755

10

Docetaxel chronopharmacology in mice.

Tampellini M, Filipski E, Liu XH, Lemaigre G, Li XM, Vrignaud P, François E, Bissery MC, Lévi F. Tampellini M, et al. Among authors: vrignaud p. Cancer Res. 1998 Sep 1;58(17):3896-904. Cancer Res. 1998. PMID: 9731500

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page